



**22 May 2020**

**OMEGA DIAGNOSTICS GROUP PLC  
("Omega" or the "Company" or the "Group")**

**Exercise of Options and Total Voting Rights**

Omega Diagnostics (AIM: ODX), the medical diagnostics company focused CD4, infectious diseases, food intolerance and allergy testing, announces that it has allotted 25,000 new ordinary shares of 4 pence each in the capital of the Company ("Ordinary Shares") following the exercise of share options by an employee.

Application has been made to the London Stock Exchange for the 25,000 new Ordinary Shares to be admitted to trading on AIM ("Admission") and it is expected that Admission will become effective and trading will commence at 8.00 a.m. on 29 May 2020.

After Admission, the total number of Ordinary Shares in issue will be 150,577,010 and the total number of voting rights will therefore be 150,577,010. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014. The below notification is made in accordance with the requirements of the EU Market Abuse Regulation.

**Contacts:**

**Omega Diagnostics Group PLC**

Bill Rhodes, Interim Non-Executive Chairman  
Colin King, Chief Executive  
Kieron Harbinson, Group Finance Director

Tel: 01259 763 030  
[www.omegadiagnostics.com](http://www.omegadiagnostics.com)

**finnCap Ltd**

Geoff Nash/Hannah Boros (Corporate Finance)  
Camille Gochez (Corporate Broking)

Tel: 020 7220 0500

**Walbrook PR Limited**

Paul McManus  
Lianne Cawthorne

Tel: 020 7933 8780 or [omega@walbrookpr.com](mailto:omega@walbrookpr.com)  
Mob: 07980 541 893  
Mob: 07584 391 303